PTEN is a tumor suppressor that is mutated in many forms of human cancer. PTEN encodes a phosphatase that recognizes the important second messenger, phosphatidylinositol-3,4,5-triphosphate (Pl- 3,4,5-P), and removes the 3'-phosphate from the inositol ring. PTEN therefore antagonizes PI-3 kinase, which phosphorylates the inositol ring at the same position. PI-3 kinase is an oncogene in its own right that is frequently mutated and amplified in tumors. Although PI-3 kinase and PTEN potentially influence many signaling pathways, perhaps the best understood pathway involving these genes is the insulin/IGF pathway, which is conserved in homo sapiens, c. elegans and drosophila. In these species, PTEN acts downstream of the insulin/IGF receptor, the insulin receptor substrate (IRS) adaptor and PI-3 kinase and upstream of AKT kinase. The most significant targets of AKT are the FOXO transcription factor genes. Activation of the PI-3 kinase pathway is highly oncogenic;however, it remains unclear how many components of the pathway contribute to oncogenesis. This application will focus on three fundamental problems in understanding how the PI-3 kinase pathway drives tumor formation.
In aim 1, we will explore the possibility that pathological over expression of IRS2 in tumors can stimulate PI-3 kinase and collaborate with other alterations on the Pl- 3 kinase pathway to boost the PI-3 kinase signal. We will introduce IRS2 into normal human cells and examine them for alterations in growth, differentiation, and signaling. The minimal domain that is competent for inducing signaling and altered growth will be defined. We will measure the frequency of over expression in tumors and measure the effect of RNAi on tumor cell line growth and signaling. Lastly, we will establish a transgenic model of IRS2 overexpression to test the hypothesis that it is an oncogene .
In aim 2, we will determine the effect of PTEN dose on tumor formation in mice. Loss of one copy of PTEN and reduced PTEN protein expression are extremely common in human malignancy. We therefore will reduce expression of PTEN in mice using RNAi and examine its effect on tumor formation.
In aim 3, we will investigate how PTEN regulates FOXO transcription factors to activate a target gene. DNA elements will be identified on the promoter that coordinate gene activation. A combination of overexpression, RNAi, and chromatin immuno- precipitation experiments are planned to identify the mechanism of activation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA082783-10
Application #
7768498
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Yassin, Rihab R,
Project Start
2001-03-03
Project End
2012-01-31
Budget Start
2010-02-01
Budget End
2012-01-31
Support Year
10
Fiscal Year
2010
Total Cost
$241,297
Indirect Cost
Name
Columbia University (N.Y.)
Department
Pathology
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Mathur, Deepti; Stratikopoulos, Elias; Ozturk, Sait et al. (2017) PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition. Cancer Discov 7:380-390
Pappas, Kyrie; Xu, Jia; Zairis, Sakellarios et al. (2017) p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes. Mol Cancer Res 15:1051-1062
Chung, Chi-Yeh; Sun, Zhen; Mullokandov, Gavriel et al. (2016) Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary Tumorigenesis. Cell Rep 16:472-486
Stratikopoulos, Elias E; Parsons, Ramon E (2016) Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue. Clin Cancer Res 22:2605-10
She, Qing-Bai; Gruvberger-Saal, Sofia K; Maurer, Matthew et al. (2016) Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer. BMC Cancer 16:587
Nguyen, H-N; Yang Jr, J-M; Rahdar, M et al. (2015) A new class of cancer-associated PTEN mutations defined by membrane translocation defects. Oncogene 34:3737-43
Stratikopoulos, Elias E; Dendy, Meaghan; Szabolcs, Matthias et al. (2015) Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. Cancer Cell 27:837-51
Keniry, Megan; Dearth, Robert K; Persans, Michael et al. (2014) New Frontiers for the NFIL3 bZIP Transcription Factor in Cancer, Metabolism and Beyond. Discoveries (Craiova) 2:e15
Hopkins, Benjamin D; Parsons, Ramon E (2014) Molecular pathways: intercellular PTEN and the potential of PTEN restoration therapy. Clin Cancer Res 20:5379-83
Hodakoski, Cindy; Hopkins, Benjamin D; Barrows, Douglas et al. (2014) Regulation of PTEN inhibition by the pleckstrin homology domain of P-REX2 during insulin signaling and glucose homeostasis. Proc Natl Acad Sci U S A 111:155-60

Showing the most recent 10 out of 31 publications